meta_analysis
    2017
    High Quality

    Glycine treatment of the risk syndrome for psychosis and adjunctive glycine in schizophrenia: a meta-analysis of NMDA-enhancing agents

    Goff DC

    Published in Schizophrenia Bulletin

    Methodology

    Review and meta-analysis of trials of glycine and other NMDA-receptor glycine-site agonists as adjuncts in schizophrenia

    Key Findings

    Pooled effects on negative symptoms were small and inconsistent, with the largest multicentre trial (CONSIST) finding no benefit of adjunctive glycine.

    Conclusions

    Adjunctive glycine has not shown reliable benefit for schizophrenia symptoms in adequately powered trials.

    Limitations

    Heterogeneous doses and background antipsychotics.

    Supplements Studied

    Glycine
    Amino Acid

    Trials of adjunctive glycine in schizophrenia have produced small and inconsistent effects, with the largest trial finding no benefit.

    Study Details

    Year:2017
    Sample Size:800
    Duration:16 weeks
    Quality Score:7/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.